tiprankstipranks
BioMarin Pharmaceutical (GB:0HNC)
LSE:0HNC
UK Market
0HNC
BioMarin Pharmaceutical
RESEARCH TOOLSreports

BioMarin Pharmaceutical (0HNC) Share Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

0HNC Analyst Ratings

Strong Buy
19Ratings
Strong Buy
15 Buy
4 Hold
0 Sell
Based on 19 analysts giving stock ratings to
BioMarin
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0HNC Stock 12 Month Forecast

Average Price Target

$94.11
▲(53.45% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $94.11 with a high forecast of $124.00 and a low forecast of $59.00. The average price target represents a 53.45% change from the last price of $61.33.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"51":"$51","88":"$88","125":"$125","69.5":"$69.5","106.5":"$106.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$124.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.11111111111111,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$94.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":59,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$59.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[51,69.5,88,106.5,125],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.59,64.54461538461538,69.49923076923078,74.45384615384616,79.40846153846154,84.36307692307693,89.31769230769231,94.27230769230769,99.22692307692307,104.18153846153847,109.13615384615385,114.09076923076924,119.04538461538462,{"y":124,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.59,62.24547008547009,64.90094017094017,67.55641025641026,70.21188034188035,72.86735042735043,75.52282051282052,78.1782905982906,80.83376068376069,83.48923076923077,86.14470085470086,88.80017094017094,91.45564102564103,{"y":94.11111111111111,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.59,59.54461538461539,59.49923076923077,59.45384615384616,59.40846153846154,59.363076923076925,59.31769230769231,59.27230769230769,59.22692307692308,59.181538461538466,59.136153846153846,59.09076923076923,59.04538461538461,{"y":59,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":57.875,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.039,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.546,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.272,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.902,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.081,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.01,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.38,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.78,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.59,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$124.00Average Price Target$94.11Lowest Price Target$59.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on GB:0HNC
Allison Bratzel
Piper Sandler
Piper Sandler
$88
Buy
43.49%
Upside
Reiterated
08/26/26
Analysts Are Bullish on Top Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Ocular Therapeutix (OCUL)
H.C. Wainwright Analyst forecast on GB:0HNC
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$60→$59
Hold
-3.80%
Downside
Reiterated
08/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Annovis Bio (NYSE: ANVS) and BioMarin Pharmaceutical (NASDAQ: BMRN)
TD Cowen Analyst forecast on GB:0HNC
Phil Nadeau
TD Cowen
TD Cowen
$120
Buy
95.66%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Canaccord Genuity Analyst forecast on GB:0HNC
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$114
Buy
85.88%
Upside
Reiterated
08/19/26
BioMarin Acquisition of Alesta Therapeutics Reinforces Growth Strategy; Whitney Ijem Reiterates Buy Rating and Maintains $114 Price Target
BMO Capital Analyst forecast on GB:0HNC
Unknown Analyst
BMO Capital
Not Ranked
BMO Capital
$98
Buy
59.79%
Upside
Initiated
08/18/26
BioMarin initiated with an Outperform at BMO CapitalBioMarin initiated with an Outperform at BMO Capital
Bank of America Securities Analyst forecast on GB:0HNC
Jason Gerberry
Bank of America Securities
Bank of America Securities
$86
Buy
40.23%
Upside
Reiterated
08/18/26
Analysts' Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Immatics (IMTX)
William Blair Analyst forecast on GB:0HNC
Sami Corwin
William Blair
William Blair
―
Hold
―
Reiterated
08/18/26
Analysts Offer Insights on Healthcare Companies: AEON Biopharma (NYSE MKT: AEON), BioMarin Pharmaceutical (NASDAQ: BMRN) and Immatics (NASDAQ: IMTX)
Wedbush Analyst forecast on GB:0HNC
Yun Zhong
Wedbush
Wedbush
$94
Buy
53.27%
Upside
Reiterated
08/18/26
Analysts' Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), BioMarin Pharmaceutical (BMRN)
Barclays Analyst forecast on GB:0HNC
Eliana Merle
Barclays
Barclays
$105→$111
Buy
80.99%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (NASDAQ: PHAT) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Stifel Nicolaus Analyst forecast on GB:0HNC
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$70
Hold
14.14%
Upside
Reiterated
08/11/26
BioMarin Pharmaceutical (BMRN) Receives a Hold from Stifel Nicolaus
Evercore ISI Analyst forecast on GB:0HNC
Cory Kasimov
Evercore ISI
Evercore ISI
$120
Buy
95.66%
Upside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cresco Labs (Other OTC: CRLBF)
Morgan Stanley Analyst forecast on GB:0HNC
Sean Laaman
Morgan Stanley
Morgan Stanley
$119→$124
Buy
102.18%
Upside
Assigned
08/07/26
Morgan Stanley Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Jefferies Analyst forecast on GB:0HNC
Akash Tewari
Jefferies
Jefferies
$104
Buy
69.57%
Upside
Reiterated
08/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wells Fargo Analyst forecast on GB:0HNC
Mohit Bansal
Wells Fargo
Wells Fargo
$75→$80
Buy
30.44%
Upside
Reiterated
08/07/26
BioMarin Pharmaceutical (BMRN) Receives a Buy from Wells Fargo
Oppenheimer Analyst forecast on GB:0HNC
Leland Gershell
Oppenheimer
Oppenheimer
$95→$97
Buy
58.16%
Upside
Assigned
08/07/26
BioMarin price target raised to $97 from $95 at OppenheimerBioMarin price target raised to $97 from $95 at Oppenheimer
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on GB:0HNC
Allison Bratzel
Piper Sandler
Piper Sandler
$88
Buy
43.49%
Upside
Reiterated
08/26/26
Analysts Are Bullish on Top Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Ocular Therapeutix (OCUL)
H.C. Wainwright Analyst forecast on GB:0HNC
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$60→$59
Hold
-3.80%
Downside
Reiterated
08/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Annovis Bio (NYSE: ANVS) and BioMarin Pharmaceutical (NASDAQ: BMRN)
TD Cowen Analyst forecast on GB:0HNC
Phil Nadeau
TD Cowen
TD Cowen
$120
Buy
95.66%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Canaccord Genuity Analyst forecast on GB:0HNC
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$114
Buy
85.88%
Upside
Reiterated
08/19/26
BioMarin Acquisition of Alesta Therapeutics Reinforces Growth Strategy; Whitney Ijem Reiterates Buy Rating and Maintains $114 Price Target
BMO Capital Analyst forecast on GB:0HNC
Unknown Analyst
BMO Capital
Not Ranked
BMO Capital
$98
Buy
59.79%
Upside
Initiated
08/18/26
BioMarin initiated with an Outperform at BMO CapitalBioMarin initiated with an Outperform at BMO Capital
Bank of America Securities Analyst forecast on GB:0HNC
Jason Gerberry
Bank of America Securities
Bank of America Securities
$86
Buy
40.23%
Upside
Reiterated
08/18/26
Analysts' Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Immatics (IMTX)
William Blair Analyst forecast on GB:0HNC
Sami Corwin
William Blair
William Blair
―
Hold
―
Reiterated
08/18/26
Analysts Offer Insights on Healthcare Companies: AEON Biopharma (NYSE MKT: AEON), BioMarin Pharmaceutical (NASDAQ: BMRN) and Immatics (NASDAQ: IMTX)
Wedbush Analyst forecast on GB:0HNC
Yun Zhong
Wedbush
Wedbush
$94
Buy
53.27%
Upside
Reiterated
08/18/26
Analysts' Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), BioMarin Pharmaceutical (BMRN)
Barclays Analyst forecast on GB:0HNC
Eliana Merle
Barclays
Barclays
$105→$111
Buy
80.99%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (NASDAQ: PHAT) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Stifel Nicolaus Analyst forecast on GB:0HNC
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$70
Hold
14.14%
Upside
Reiterated
08/11/26
BioMarin Pharmaceutical (BMRN) Receives a Hold from Stifel Nicolaus
Evercore ISI Analyst forecast on GB:0HNC
Cory Kasimov
Evercore ISI
Evercore ISI
$120
Buy
95.66%
Upside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cresco Labs (Other OTC: CRLBF)
Morgan Stanley Analyst forecast on GB:0HNC
Sean Laaman
Morgan Stanley
Morgan Stanley
$119→$124
Buy
102.18%
Upside
Assigned
08/07/26
Morgan Stanley Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Jefferies Analyst forecast on GB:0HNC
Akash Tewari
Jefferies
Jefferies
$104
Buy
69.57%
Upside
Reiterated
08/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wells Fargo Analyst forecast on GB:0HNC
Mohit Bansal
Wells Fargo
Wells Fargo
$75→$80
Buy
30.44%
Upside
Reiterated
08/07/26
BioMarin Pharmaceutical (BMRN) Receives a Buy from Wells Fargo
Oppenheimer Analyst forecast on GB:0HNC
Leland Gershell
Oppenheimer
Oppenheimer
$95→$97
Buy
58.16%
Upside
Assigned
08/07/26
BioMarin price target raised to $97 from $95 at OppenheimerBioMarin price target raised to $97 from $95 at Oppenheimer
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

3 Months
Christopher RaymondRaymond James
Success Rate
16/36 ratings generated profit
44%
Average Return
>-0.01%
Copying Christopher Raymond's trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of >-0.01% per trade.
1 Year
Cory KasimovEvercore ISI
Success Rate
22/43 ratings generated profit
51%
Average Return
-2.37%
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 51.16% of your transactions generating a profit, with an average return of -2.37% per trade.
2 Years
Phil NadeauTD Cowen
Success Rate
17/26 ratings generated profit
65%
Average Return
+0.13%
Copying Phil Nadeau's trades and holding each position for 2 Years would result in 65.38% of your transactions generating a profit, with an average return of +0.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HNC Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
13
27
26
25
14
Buy
13
11
6
7
9
Hold
6
10
10
13
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
48
42
45
34
In the current month, 0HNC has received 23 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. 0HNC average Analyst price target in the past 3 months is 94.11.
Each month's total comprises the sum of three months' worth of ratings.

0HNC Financial Forecast

0HNC Earnings Forecast

Next quarter’s earnings estimate for 0HNC is $1.35 with a range of $1.22 to $1.48. The previous quarter’s EPS was $1.20. 0HNC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HNC has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0HNC is $1.35 with a range of $1.22 to $1.48. The previous quarter’s EPS was $1.20. 0HNC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HNC has Performed in-line its overall industry.

0HNC Sales Forecast

Next quarter’s sales forecast for 0HNC is $1.03B with a range of $1.00B to $1.07B. The previous quarter’s sales results were $996.38M. 0HNC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HNC has Performed in-line its overall industry.
Next quarter’s sales forecast for 0HNC is $1.03B with a range of $1.00B to $1.07B. The previous quarter’s sales results were $996.38M. 0HNC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HNC has Performed in-line its overall industry.

0HNC Stock Forecast FAQ

What is GB:0HNC’s average 12-month price target, according to analysts?
Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is 94.11.
    What is GB:0HNC’s upside potential, based on the analysts’ average price target?
    BioMarin Pharmaceutical has 53.45% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BioMarin Pharmaceutical a Buy, Sell or Hold?
          BioMarin Pharmaceutical has a consensus rating of Strong Buy, which is based on 15 buy ratings, 4 hold ratings and 0 sell ratings.
            What is BioMarin Pharmaceutical’s share price target?
            The average share price target for BioMarin Pharmaceutical is 94.11. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $124.00 ,and the lowest forecast is $59.00. The average share price target represents 53.45% Increase from the current price of $61.33.
              What do analysts say about BioMarin Pharmaceutical?
              BioMarin Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of BioMarin Pharmaceutical?
                To buy shares of GB:0HNC, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.